Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

IMPROVE-IT Study: Negative Panel Review Leaves FDA With Tough Choice

Executive Summary

Approval of cardiovascular risk reduction claims for Merck's Zetia and Vytorin would fly in the face of advisory committee's recommendations, but rejection would mean the first outcomes study to show CV benefit for a non-statin, LDL-C-lowering agent did not provide substantial evidence.

Advertisement

Related Content

Keeping Track: FDA Approves Briviact, Refuses To File Firdapse, Rejects Remune
FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo
Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
The Califf Factor: Commissioner Nominee's Role In IMPROVE-IT Gets Notice
The SHARP “Approval”: Merck Gets Vytorin Labeling Change, But Not The CV Outcomes Claim It Sought
Merck's Vytorin/Zetia Headed For CV Outcomes Claim, But Will Dialysis Patients Be Off-Limits?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel